Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: WeirdPro Randy who wrote (1050)	2/18/1998 2:46:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1359

I do hope their research expertise is not as shoddy as their reliance upon these numbers would indicate. The best estimate of total US individuals taking Redux ever is between 1.5-2 million. IMS America figures for prescriptions written (this is the 'bible' of prescription drug activity) includes a lot of duplications, because the schedule status of both Pondimin and Redux required rewriting scrips every month or two, and if patients changed prescribers and/or drugstores, a repeat prescription could/would be classified as 'new.' Furthermore, the 33% figure likely gleaned from the first 291 patient pool assembled by Mayo Clinic turned out to not apply to Redux; only 13% of the Redux users in the sample had any reports of valvular pathology. 13% times 2 million= 260,000. As previous posts of mine have noted, even this calculation leaves out the critical variable of duration of use, and with only 5% of Redux users having taken Redux 6 months or more....that would reduce the 'at risk' pool still further. NeuroInvestment (www.neuroinv.com)